What the label says
The boxed warning is about thyroid C-cell tumors—not every thyroid condition
The June 18, 2026 manufacturer label says semaglutide caused dose- and duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures. It also says the human relevance is unknown and that it is unknown whether Wegovy causes thyroid C-cell tumors, including MTC, in humans. Wegovy is contraindicated with a personal or family history of MTC or MEN 2. Hypothyroidism and Hashimoto’s disease are different clinical questions and are not named among those contraindications, but the prescriber still needs the exact diagnosis and family history before deciding whether treatment fits.
- Do not shorten the warning to “Wegovy causes thyroid cancer” or assume it refers to every thyroid nodule, thyroid-replacement prescription, or abnormal TSH result.
- Do not hide or relabel a personal or family history of MTC or MEN 2 to obtain a prescription.
- Bring pathology, surgery, endocrinology, genetic-testing, or family-history details when the thyroid diagnosis is uncertain.
Hypothyroidism assessment
Stable underactive-thyroid treatment and unexplained symptoms need different reviews
Hypothyroidism can involve fatigue, weight gain, cold intolerance, constipation, dry skin, hair changes, slowed heart rate, menstrual changes, depression, or goiter. Many of those concerns can overlap with weight-management goals, nutrition changes, gastrointestinal effects, dehydration, mood, sleep, or other medicines. A clinician may review the cause of hypothyroidism, current thyroid prescription, adherence, symptoms, recent TSH and free-thyroxine results when available, major weight change, pregnancy context, and whether endocrinology follow-up is already needed. Wegovy does not replace thyroid hormone or establish why a symptom is occurring.
- Do not use levothyroxine, liothyronine, iodine, or another thyroid product as a weight-loss add-on or change it to accelerate Wegovy results.
- An abnormal thyroid result may need interpretation before or during care, but one number does not create an automatic Wegovy approval, denial, pause, or dose change.
- Share severe gastrointestinal symptoms, reduced intake, rapid weight change, and adherence problems because they can complicate symptom and laboratory interpretation.
Nodules and neck symptoms
A thyroid nodule or concerning neck symptom needs evaluation—not a home screening plan
The Wegovy label says patients with thyroid nodules found on examination or neck imaging should be further evaluated. It also says routine serum-calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection in patients treated with Wegovy because of low test specificity and the background rate of thyroid disease. That means an identified concern should not be ignored, but it also does not support ordering repeated screening tests for everyone from a generic checklist.
- Promptly report a new neck mass, persistent hoarseness, trouble swallowing, or trouble breathing to the appropriate clinician.
- Do not interpret calcitonin, ultrasound, biopsy, or genetic results without the clinician responsible for thyroid evaluation.
- Do not delay an indicated thyroid workup while waiting for a telehealth weight-management decision.
Injection, tablet, and levothyroxine
Route identity changes the medication-timing question
Current Wegovy labeling includes injection and once-daily tablet presentations. The tablet is taken in the morning on an empty stomach with water only, followed by at least 30 minutes before food, beverages, or other oral medicines. The same label reports that levothyroxine exposure increased 33% in a semaglutide-tablet interaction study and advises monitoring relevant oral medicines. That finding should not be converted into a universal spacing interval, thyroid-dose change, or claim that weekly Wegovy injection has the same studied interaction. A prescriber or pharmacist should reconcile the exact Wegovy route, levothyroxine product, pharmacy directions, thyroid history, other morning medicines, and laboratory plan.
- Do not take the Wegovy tablet and levothyroxine together unless the prescriber or pharmacist specifically directs that routine.
- Do not switch between tablet and injection presentations, copy a conversion chart, or move thyroid medicine to a new time on your own.
- Confirm the manufacturer, route, strength, bottle or injection presentation, pharmacy label, and indication before applying product-specific instructions.
Product and care boundaries
Branded Wegovy and compounded semaglutide are not the same finished product
Wegovy is an FDA-approved semaglutide brand with current presentation- and indication-specific labeling. A patient-specific compounded semaglutide preparation is not FDA-approved Wegovy, an FDA-approved generic Wegovy, or proof that the same container, ingredients, concentration, storage, administration, interaction, and coverage rules apply. Eligibility for any prescription still requires individual clinical review. Online sellers that offer automatic approval, “research” semaglutide for patient use, hidden pharmacy sourcing, or thyroid-safe guarantees should be avoided.
- Use the current prescription label and manufacturer information, not a seller’s copied Wegovy name or stock image.
- Ask who prescribes, which licensed pharmacy dispenses, how the exact product is identified, what follow-up is included, and how adverse events are handled.
- Do not use compounded medication to bypass an MTC or MEN 2 contraindication or an unresolved thyroid evaluation.
When to get help
Escalate severe symptoms instead of assuming they are “just thyroid” or “just Wegovy”
Routine eligibility, thyroid-lab, medication-timing, and mild symptom questions can usually start with the prescriber, thyroid clinician, or pharmacist. Severe or rapidly worsening symptoms need prompt assessment. A person should not assume that neck symptoms, faintness, repeated vomiting, severe abdominal pain, marked glucose changes, or allergic symptoms are explained by hypothyroidism or expected Wegovy effects.
- Seek prompt care for trouble breathing, facial or throat swelling, fainting, confusion, chest pain, severe weakness, or a rapidly enlarging neck mass.
- Repeated vomiting, inability to keep fluids down, markedly reduced urination, severe persistent abdominal pain, jaundice, or severe glucose symptoms also need prompt assessment.
- Contact the responsible clinician before the next treatment decision for persistent symptoms, an abnormal thyroid result, pregnancy, a new neck finding, or uncertainty about either pharmacy label.